

BEST AVAILABLE COPY

Appl. No. 10/007,459
Amtd. dated 11/2/2006
Reply to Notice of October 26, 2006

RECEIVED
CENTRAL FAX CENTER

NOV 02 2006

AMENDMENTS TO THE CLAIMS

In the claims, please amend claims 11, 14, and 18 as follows:

1-10. (canceled)

11. (currently amended) A process for inhibiting expression of a gene in a parenchymal cell in a target tissue in a mammal, comprising:

- a) mixing a double strand RNA oligonucleotide consisting of a sequence that is substantially complementary a portion of a sequence of the gene and a compound selected from the group consisting of amphipathic compounds, polymers and non-viral vectors to form a complex wherein the zeta potential of the complex is less negative than the zeta potential of the double strand RNA oligonucleotide alone;
- b) inserting the complex into an efferent or afferent mammalian vessel of the target tissue *in vivo* thereby increasing permeability of vessels within the target tissue and delivering the double strand RNA oligonucleotide to the parenchymal cell, wherein the double strand RNA oligonucleotide inhibits expression of the gene.

12. (canceled)

13. (previously presented) The process of claim 11 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.

14. (currently amended) The process of claim 13 wherein the parenchymal cell is selected from the group consisting of liver cells, spleen cells, heart cells, kidney cells, prostate cells, skin cells, testis cells, skeletal muscle cells, fat, bladder cells, brain cells, pancreas cells, thymus cells, and lung cells.

15. (previously presented) The process of claim 11 wherein the complex has a positive charge.

16. (previously presented) The process of claim 11 wherein the complex has a negative charge.

17. (previously presented) The process of claim 13 wherein increasing the pressure consists of increasing volume of fluid within the vessel.


18. (currently amended) The process of claim 17 wherein the fluid solution is inserted within 2 minutes.

BEST AVAILABLE COPY

Appl. No. 10/007,459
Amdt. dated 11/2/2006
Reply to Notice of October 26, 2006

If there are any questions or concerns, please contact the undersigned.

Respectfully submitted,



Kirk Ekena, Reg. No. 56,672
Mirus Bio Corporation
505 South Rosa Road
Madison, WI 53719
608-238-4400

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: November 2, 2006.


Kirk Ekena/
Kirk Ekena